Archives

by in
Entry Author Date Location
J&J Prostate Cancer Trial Shouldn’t Have Been Stopped Early 06/03/12 National
Basic Biology: The Complex Core of Drug Discovery 05/30/12 Seattle
A 10-Point Plan to Stimulate Biotech & the Economy as a Whole 05/09/12 National
First Comes The $1,000 genome, Then Comes The $10,000 Analysis 05/08/12 Seattle
Virtual Biotech Companies: Built on Solid Bedrock or Unstable Landfill? 05/03/12 Seattle
5 Things to Do Before the New Patent Law Takes Full Effect 05/02/12 San Diego
Taking Open Biology to the Next Level: Notes from the Sage Congress 04/27/12 National
The JOBS Act—The “IPO On-Ramp” Makes IPOs Easier 04/24/12 Boston
BioPharma Needs A Safe, Reliable Way To Repair Broken Genes 04/11/12 Seattle
Glaxo and J&J’s Shrewd Move Will Help the Biotech Ecosystem 03/23/12 National
The Supreme Court’s Bad Precedent for Innovation 03/22/12 National
A Seussian Guide to BioPharma 03/13/12 National
Will New Business Models Enhance or Endanger Drug Discovery? 02/16/12 National
Biogen Idec Lets Stromedix Do The Hard Part 02/14/12 Boston
Four Themes to Watch in Personalized Medicine 01/30/12 San Francisco
Vision Without Execution is Hallucination 01/30/12 San Francisco
Angry at the Genome 01/25/12 Boston
From AI to Bioengineering 01/18/12 San Francisco
Biology 101 01/18/12 Boston
Global Healthcare 01/18/12 New York
Reinventing the Board Part III: The Agenda 01/17/12 Boston
JP Morgan: Where the Boys Are…And Not the Girls 01/16/12 San Francisco
Greenwashing 01/12/12 San Diego
Me-Too Drugs 01/11/12 San Diego
Regulatory Overkill 01/11/12 San Diego
The Situation at the FDA: We Are All to Blame 01/10/12 San Francisco
Of Patent Rats and Blaming Teachers 01/10/12 Seattle
Lack of Funding For Innovative Biotech Companies 01/09/12 Detroit
Diabetes Drugs Could Cure Cancer 01/03/12 San Francisco
Healthcare That Works 01/03/12 Boston
Page 3 of 8 « previous page · next page »